Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting
NCT ID: NCT02036944
Last Updated: 2016-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
13 participants
OBSERVATIONAL
2014-03-31
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is hypothesized that selectively screening patients with unexplained iron deficiency will reveal previously undiagnosed etiologies, including celiac disease and other causes of iron malabsorption along with various sources of occult GI blood loss.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of a Dietary Approach to Iron Deficiency in Premenopausal Women Affected by Celiac Disease
NCT02949765
Iron Deficiency and TTG Normalization
NCT05675280
Celiac Disease Screening
NCT01902368
Nutritional Intake and Bone Health in Celiac Disease
NCT03364556
Characteristics of Anemia in Celiac Disease
NCT05172895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Prevalence of specific serum markers of celiac disease in those with unexplained serum markers of iron deficiency.
* Prevalence of iron malabsorption with and without celiac disease in the same population
* Frequency of other blood tests for malabsorption and their association with celiac disease or other cause of iron malabsorption.
* Frequency of specific historical markers associated with celiac disease
* Prevalence of unrecognized GI blood loss
* Quality of life improvement based on new diagnoses with appropriate therapy
* After one year follow-up, review patient records for additional diagnoses explaining iron deficiency.
Primary Objective:
Discover several etiologies of unexplained iron deficiency in a primary care clinic population including celiac disease, iron malabsorption and occult intestinal blood loss.
Secondary Objectives:
* Define percent of total clinic patient population with one or more markers of iron deficiency on last testing and the subset without an apparent etiology on their problem list ("study group").
* Define percent of patients in the study group that are currently iron deficient at time of study onset, and how many of those are actually anemic.
* Define percent of study group patients with iron malabsorption, with or without celiac disease.
* Document improved quality of life outcomes for those with new diagnoses and appropriate therapy, including celiac disease given gluten-free diet and iron therapy.
* For those patients identified with celiac disease, do statistical analysis of historical and lab parameters that are more highly linked to celiac disease to improve screening parameters.
* Document percent of various diagnoses that explain occult iron deficiency as found by primary care providers over the course of a one year follow-up after initial diagnosis. (Providers will be given all testing results related to their patients after the initial screening and at one year.)
* Specific cost-effectiveness of this screening procedure may be done in a future study if preliminary results are suggestive of improved outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Demographic Age \> 18 years. Diagnostic criteria: markers of iron deficiency at last check are defined as MCV\<80 fL, Iron Sat\<20% or ferritin\<30 ng/mL.
3. Patient signs informed consent document and HIPAA authorization for release of personal health information.
4. Ability to understand procedures and comply with them for one year duration of study
Exclusion Criteria
1. Acute blood loss requiring iron treatment or transfusions within 1 year prior to the above measure of iron deficiency
2. Chronic blood loss (such as menorrhagia, GI bleeding, hemoptysis, hematuria, chronic nose bleeds, hemolysis, regular blood donations, or major trauma requiring transfusion or iron therapy)
3. Thalassemia or other major hemolytic diseases.
2. Prior diagnosis of celiac disease, or other documented cause of iron malabsorption.
3. Women who are currently pregnant, or who were pregnant with 6 months prior to time of last testing.
4. Those currently or recently on chemotherapy (within the last 6 months)
5. Those with prior gastric resection or bariatric surgery
6. Those with advanced chronic kidney disease (stage 4 or 5)
7. Any other reasons that, in the investigators' opinion, may prevent compliance with protocol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Providence Sacred Heart Medical Center & Children's Hospital
OTHER
Providence Medical Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel Palpant, MD
Role: PRINCIPAL_INVESTIGATOR
Providence Internal Medicine Residency Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Medical Research Center
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMRC-1909-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.